The Effects of Temozolomide Analog (TMZ-A) on LN229 and U87 Glioblastoma Cell Lines
School Name
South Carolina Governor's School for Science & Mathematics
Grade Level
12th Grade
Presentation Topic
Cell and Molecular Biology
Presentation Type
Mentored
Abstract
Glioblastoma is the most common and deadly type of brain cancer. A common drug used to treat glioblastoma is Temozolomide (TMZ), but it is known to have detrimental side effects. The purpose of this research is to determine if a modified version of TMZ (TMZ-A—TMZ with an added carboxylic acid) will have the same cell death efficacy as unmodified TMZ. Two glioblastoma cell lines, U87 and LN229, were treated with various concentrations of TMZ and TMZ-A [0-100 μM] up to 48 or 72 hours. The results indicate that TMZ-A was more effective in causing cell death with concentrations of 100 μM in either 48 or 72-hour periods as compared to TMZ in U87 cell lines. The results of TMZ-A on the LN229 cell line indicated significant (>90%) cell death with concentrations of 1 μM and 100 μM of treatment up to 48 hours, and concentrations ranging from 10-100 μM of treatment up to 72 hours. Due to time constraint effect of TMZ on the LN229 cell line could not be achieved. These are preliminary results. Therefore, these experiments need to be repeated due to discrepancies in the protocol. In the future, it would be valuable to the repeat the research with other cell lines, at various time periods, and with more TMZ analogs, in order to optimize the drug’s efficacy.
Recommended Citation
Salazar, Paula, "The Effects of Temozolomide Analog (TMZ-A) on LN229 and U87 Glioblastoma Cell Lines" (2019). South Carolina Junior Academy of Science. 264.
https://scholarexchange.furman.edu/scjas/2019/all/264
Location
Founders Hall 114 A
Start Date
3-30-2019 8:30 AM
Presentation Format
Oral Only
Group Project
No
The Effects of Temozolomide Analog (TMZ-A) on LN229 and U87 Glioblastoma Cell Lines
Founders Hall 114 A
Glioblastoma is the most common and deadly type of brain cancer. A common drug used to treat glioblastoma is Temozolomide (TMZ), but it is known to have detrimental side effects. The purpose of this research is to determine if a modified version of TMZ (TMZ-A—TMZ with an added carboxylic acid) will have the same cell death efficacy as unmodified TMZ. Two glioblastoma cell lines, U87 and LN229, were treated with various concentrations of TMZ and TMZ-A [0-100 μM] up to 48 or 72 hours. The results indicate that TMZ-A was more effective in causing cell death with concentrations of 100 μM in either 48 or 72-hour periods as compared to TMZ in U87 cell lines. The results of TMZ-A on the LN229 cell line indicated significant (>90%) cell death with concentrations of 1 μM and 100 μM of treatment up to 48 hours, and concentrations ranging from 10-100 μM of treatment up to 72 hours. Due to time constraint effect of TMZ on the LN229 cell line could not be achieved. These are preliminary results. Therefore, these experiments need to be repeated due to discrepancies in the protocol. In the future, it would be valuable to the repeat the research with other cell lines, at various time periods, and with more TMZ analogs, in order to optimize the drug’s efficacy.
